Press release
Focal Segmental Glomerulosclerosis Pipeline Insights 2025 by DelveInsight | Dimerix Bioscience, Travere Therapeutics, Horizon Therapeutics, Pfizer, Goldfinch Bio, Certa Therapeutics, ZyVersa Therapeut
Focal Segmental Glomerulosclerosis Pipeline Insights
DelveInsight's analysis shows that the Focal Segmental Glomerulosclerosis (FSGS) pipeline involves over 15 key companies actively developing more than 18 therapies for FSGS treatment.
Focal Segmental Glomerulosclerosis Overview:
Focal Segmental Glomerulosclerosis (FSGS) is a major cause of idiopathic steroid-resistant nephrotic syndrome (SRNS) and can progress to end-stage kidney disease (ESKD). Its development involves complex interactions among multiple cell types, including podocytes, endothelial cells, and the glomerular basement membrane. Podocytes-highly specialized, non-regenerative cells-are essential for maintaining glomerular structure and the integrity of the filtration barrier, preventing excessive protein loss in urine. Damage or loss of podocytes prompts compensatory hypertrophy in the remaining cells, resulting in foot process effacement and proteinuria.
As FSGS progresses, there is proliferation of mesangial, endothelial, and epithelial cells, followed by collapse or contraction of glomerular capillaries, ultimately causing glomerulosclerosis (scarring of the glomeruli). Podocyte injury can be triggered by viral or toxic exposures or changes in intrarenal blood flow, such as elevated glomerular pressure and hyperperfusion.
Several morphological variants of FSGS have been described, including the collapsing type (linked to mesangial hypercellularity), the cellular variant (marked by endocapillary and extracapillary hypercellularity), and the tip lesion variant.
Download our report @ https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Focal Segmental Glomerulosclerosis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Focal Segmental Glomerulosclerosis Therapeutics Market.
Key Takeaways from the Focal Segmental Glomerulosclerosis Pipeline Report
*
DelveInsight's Focal Segmental Glomerulosclerosis (FSGS) pipeline report highlights a dynamic landscape, with over 15 active companies developing more than 18 therapies for FSGS treatment.
*
In March 2025, Travere Therapeutics submitted a supplemental New Drug Application (sNDA) to the FDA requesting priority review for FILSPARI Registered (sparsentan) as a treatment for FSGS. If approved, FILSPARI would become the first FDA-approved therapy for this rare kidney disease.
*
The sNDA is supported by data from the Phase 3 DUPLEX Study and Phase 2 DUET Study, among the largest interventional trials conducted in FSGS patients. While the DUPLEX Study did not achieve its primary efficacy endpoint over 108 weeks, it showed notable proteinuria reduction and higher remission rates compared to the active control.
*
Travere's pursuit of FDA approval is based on the significant reduction in proteinuria, which is recognized as a meaningful marker of treatment benefit in FSGS. The FDA has indicated willingness to consider proteinuria reduction as a surrogate endpoint for approval in FSGS therapies.
*
Key companies involved in FSGS drug development include Dimerix Bioscience, Travere Therapeutics, Horizon Therapeutics, Pfizer, Goldfinch Bio, Certa Therapeutics, ZyVersa Therapeutics, Vertex Pharmaceuticals, Chinook Therapeutics, Delta 4, and others.
*
Prominent pipeline candidates at various stages of development include DMX-200, Sparsentan, Dazodalibep, and others.
Focal Segmental Glomerulosclerosis Pipeline Analysis
The Focal Segmental Glomerulosclerosis pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Focal Segmental Glomerulosclerosis Market.
*
Categorizes Focal Segmental Glomerulosclerosis therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Focal Segmental Glomerulosclerosis drugs under development based on:
*
Stage of development
*
Focal Segmental Glomerulosclerosis Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Focal Segmental Glomerulosclerosis Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Focal Segmental Glomerulosclerosis Licensing agreements
*
Funding and investment activities supporting future Focal Segmental Glomerulosclerosis market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Focal Segmental Glomerulosclerosis Emerging Drugs
*
DMX-200: Dimerix Bioscience
*
Sparsentan: Travere Therapeutics
*
Dazodalibep: Horizon Therapeutics
Focal Segmental Glomerulosclerosis Companies
Around 15 or more prominent companies are actively working on developing therapies for Focal Segmental Glomerulosclerosis (FSGS). Among these, Dimerix Bioscience stands out with a drug candidate that has reached the most advanced stage of development-Phase III clinical trials.
DelveInsight's report covers around 18+ products under different phases of Focal Segmental Glomerulosclerosis clinical trials like
*
Focal Segmental Glomerulosclerosis Late stage Therapies (Phase III)
*
Focal Segmental Glomerulosclerosis Mid-stage Therapies (Phase II)
*
Focal Segmental Glomerulosclerosis Early-stage Therapies (Phase I)
*
Focal Segmental Glomerulosclerosis Pre-clinical and Focal Segmental Glomerulosclerosis Discovery stage Therapies
*
Focal Segmental Glomerulosclerosis Discontinued & Inactive Therapies
Focal Segmental Glomerulosclerosis pipeline report provides the Focal Segmental Glomerulosclerosis therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Focal Segmental Glomerulosclerosis Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Focal Segmental Glomerulosclerosis Therapies and Key Focal Segmental Glomerulosclerosis Companies: Focal Segmental Glomerulosclerosis Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Focal Segmental Glomerulosclerosis Pipeline Therapeutic Assessment
- Focal Segmental Glomerulosclerosis Assessment by Product Type
- Focal Segmental Glomerulosclerosis By Stage
- Focal Segmental Glomerulosclerosis Assessment by Route of Administration
- Focal Segmental Glomerulosclerosis Assessment by Molecule Type
Download Focal Segmental Glomerulosclerosis Sample report to know in detail about the Focal Segmental Glomerulosclerosis treatment market @ Focal Segmental Glomerulosclerosis Therapeutic Assessment [https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Focal Segmental Glomerulosclerosis Current Treatment Patterns
4. Focal Segmental Glomerulosclerosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Focal Segmental Glomerulosclerosis Late-Stage Products (Phase-III)
7. Focal Segmental Glomerulosclerosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Focal Segmental Glomerulosclerosis Discontinued Products
13. Focal Segmental Glomerulosclerosis Product Profiles
14. Focal Segmental Glomerulosclerosis Key Companies
15. Focal Segmental Glomerulosclerosis Key Products
16. Dormant and Discontinued Products
17. Focal Segmental Glomerulosclerosis Unmet Needs
18. Focal Segmental Glomerulosclerosis Future Perspectives
19. Focal Segmental Glomerulosclerosis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Focal Segmental Glomerulosclerosis Pipeline Reports Offerings [https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=focal-segmental-glomerulosclerosis-pipeline-insights-2025-by-delveinsight-dimerix-bioscience-travere-therapeutics-horizon-therapeutics-pfizer-goldfinch-bio-certa-therapeutics-zyversa-therapeut]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Focal Segmental Glomerulosclerosis Pipeline Insights 2025 by DelveInsight | Dimerix Bioscience, Travere Therapeutics, Horizon Therapeutics, Pfizer, Goldfinch Bio, Certa Therapeutics, ZyVersa Therapeut here
News-ID: 4161223 • Views: …
More Releases from ABNewswire
Phenix City Medical Practice Announces Expanded Healthcare Services, Addressing …
Preferred Medical Group, Phenix City, announces the expansion of its healthcare services and improved patient access, addressing community demand for comprehensive medical care with integrated pediatric, adult, and therapeutic services under one roof.
Preferred Medical Group, Phenix City [https://preferredmedgroup.com/], has announced significant enhancements to its healthcare services, responding to increased community demand for accessible and comprehensive medical care. The medical practice, located at 3700 South Railroad Street, has introduced streamlined patient…
Auburn Medical Practice Expands Integrated Care Model as Primary Care Doctor Add …
Preferred Medical Group - Auburn expands ADHD services and integrated care model, offering comprehensive family medicine, behavioral health, and specialized attention disorder treatment in one convenient East Alabama location.
Preferred Medical Group - Auburn [https://preferredmedgroup.com/] has announced significant enhancements to its integrated healthcare services, responding to increased demand for ADHD treatment and comprehensive family medical care in East Alabama. The Auburn location, situated at 318 Samford Village Court, Suite 100, now…
Local ADHD Doctor Program Launches at Preferred Medical Group - Opelika for East …
Preferred Medical Group - Opelika launches an integrated ADHD treatment program that combines pediatric care, psychiatry, and therapy services to address regional healthcare needs for East Alabama families.
Opelika healthcare providers have taken a significant step toward addressing the growing need for specialized attention deficit hyperactivity disorder services in East Alabama. Preferred Medical Group - Opelika [https://preferredmedgroup.com/] has announced the expansion of comprehensive ADHD treatment programs, integrating pediatric care with behavioral…
Prominent Criminal Lawyer in Galveston Firm Celebrates 25+ Years of Texas Gulf C …
Tad Nelson & Associates celebrates over 25 years of criminal defense excellence across the Texas Gulf Coast, combining local roots, community involvement, and personalized legal services that span multiple counties.
A prominent Texas law firm has reached a significant milestone, celebrating over 25 years of providing criminal defense and family law services across the Greater Houston area and Galveston County. The achievement underscores the firm's steadfast commitment to serving Texas communities…
More Releases for Focal
Focal Epilepsy Market New Product Development & Latest Trends
Introduction
Focal epilepsy, the most common form of epilepsy worldwide, originates in specific regions of the brain and often presents with partial seizures. Affecting millions of people globally, focal epilepsy remains a pressing neurological challenge with significant clinical and economic impact. Increasing diagnosis rates, technological advances in imaging and neurostimulation, and new pharmacological approaches are fueling rapid changes in the treatment landscape.
As healthcare systems place greater emphasis on effective long-term management…
Focal Segmental Glomerulosclerosis Market Size Report 2024
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Focal Segmental Glomerulosclerosis Drugs Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $22.41 billion In…
3D FOCAL LINES SPATULA TECHNOLOGY for SYGMALIFT
Focal Ultrasounds in three-dimensional (3D) technology expand to the Face Lifting and V Facing. This innovation is able to treat volume that contains every conceivable plane (X, Y, Z angles) within the region of interest such as Double Chin or Cheeks.
While there is no doubt that there are advantages to volume treatment in 2.5 Seconds only, it delivers more power and add clinical benefit to target submental and jawlines…
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics - Pipeline Analysis 2018
Focal segmental glomerulosclerosis (FSGS) is a glomerular disease, which is characterized by scarring or sclerosis in the kidney. Scarring damages the limited number of glomeruli in the initial stages. It is more common in males than in females, anad is very common in African American population.
Download the sample report @ https://www.pharmaproff.com/request-sample/1090
FSGS can be caused by many diseases like diabetes, sickle cell disease, and HIV infection. It is categorized into two…
Focal Segmental Glomerulosclerosis (FSGS) Market Report 2018: Segmentation by Di …
Global Focal Segmental Glomerulosclerosis (FSGS) market research report provides company profile for Variant Pharmaceuticals, Inc., GlaxoSmithKline plc., Novartis AG, ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., AstraZeneca plc., Pfizer, Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth…
Africa Energy Week – Three Different Focal Points, One Conference
Africa’s development in oil and gas has significantly increased over the last few years; Ghana’s Jubilee field, first discovered in 2007, is now producing 70,000 barrels a day and may climb to 120,000 by the end of the year. With much of its oil for export, the country’s economic growth is climbing at a rapid rate, and many are looking to follow suit. Local content has since been a hot…
